The study is to evaluate the safety, feasibility, and preliminary efficacy of frozen FMT delivery via retention enema compared to lyophilized powder given in oral capsules as induction FMT in subjects with active UC. This study will also determine changes in microbiome (diversity and genera) and proportion of antibody-coated microbiota from baseline to after completion of FMT.

Start Date15 Dec 2023

Sponsor / Collaborator

University of Texas Health Science Center at Houston

NCT04371653 / WithdrawnPhase 2IIT

A Prospective, Randomized, Placebo-Controlled Pilot Study to Characterize the Intestinal Microbiome and to Evaluate the Safety and Fecal Microbiome Changes Following Twice Weekly Administration of Lyophilized PRIM-DJ2727 or Placebo Given Orally for 12 Weeks in Subjects With Nonalcoholic Fatty Liver Disease (NAFLD)

Potential subjects with non-alcoholic fatty liver disease (NAFLD) will be identified by gastroenterologists (study investigators). Twelve eligible subjects with NAFLD will be randomly assigned to receive either active fecal microbiota transplantation in orally administered capsules or Placebo capsules and dosed twice weekly for 12 weeks. .

Start Date01 Dec 2023

Sponsor / Collaborator

University of Texas Health Science Center at Houston

NCT04373473 / RecruitingPhase 2IIT

A Phase 2a, Randomized, Double-blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lyophilized Fecal Microbiota Transplantation (PRIM-DJ2727) Administered Orally in Combination With Standard of Care Therapy for Prevention of Relapse or Intestinal Inflammation in Adults With Ulcerative Colitis

The purpose of the study is to evaluate the efficacy and safety of lyophilized PRIM-DJ2727 capsules given orally in subjects with ulcerative colitis at remission stage. This study will also include longitudinal analyses of recipient's gut microbiota taxonomy and metagenomics to determine potential associations with clinical outcomes in context of active FMT or placebo administration.

Start Date14 Sep 2020

Sponsor / Collaborator

University of Texas Health Science Center at Houston

100 Clinical Results associated with PRIM-DJ2727

100 Translational Medicine associated with PRIM-DJ2727

100 Patents (Medical) associated with PRIM-DJ2727

100 Deals associated with PRIM-DJ2727

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Metabolic dysfunction-associated steatotic liver disease	Phase 2	-	University of Texas Health Science Center at Houston	01 Dec 2023
Clostridium difficile infection	Phase 2	US	University of Texas Health Science Center at Houston	21 Dec 2017
Colitis, Ulcerative	Phase 1	US	University of Texas Health Science Center at Houston	15 Dec 2023
Parkinson Disease	Phase 1	US	University of Texas Health Science Center at Houston	15 May 2019
HIV Infections	Phase 1	US	University of Texas Health Science Center at Houston	12 Apr 2018

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


MDS2021	Not Applicable	Parkinson Disease	12	PRIM-DJ2727 capsules	fnmltrjlbl(ktbdizlvkl) = ecswntifij wbwjmthflw (hcknratruy ) View more	-	17 Sep 2021
NCT03298048 (CTgov)	Phase 2	Clostridium difficile infection	17	Low fecal microbiota dose (Low Fecal Microbiota Dose)	jrrgxsvxcz(ukvsxydfxc) = ikeoaudeuq tsqsgvouua (vfhqxdzbdq, jodkhhrpwd - xnccmpmmga) View more	-	06 Mar 2020
NCT03298048 (CTgov)	Phase 2	Clostridium difficile infection	17	Mid fecal microbiota dose (Mid Fecal Microbiota Dose)	jrrgxsvxcz(ukvsxydfxc) = omjtyzyeqe tsqsgvouua (vfhqxdzbdq, wbypbshtbu - dyudisbinf) View more	-	06 Mar 2020

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

PRIM-DJ2727

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation